APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy

Future Oncology

Volumn 12, Issue 12, 2016, Pages 1469-1481

  Schnadig, Ian D ^a   Agajanian, Richy ^b   Dakhil, Christopher ^c   Gabrail, Nashat Y ^d   Smith, Robert E ^e   Taylor, Charles ^f   Wilks, Sharon T ^g   Schwartzberg, Lee S ^h   Cooper, William ⁱ   Mosier, Michael C ^j   Payne, J Yvette ^k   Klepper, Michael J ^l   Vacirca, Jeffrey L ^m  

^a Medical Oncology Hematology   (United States)

^b Oncology Institute of Hope and Innovation   (United States)

^c Cancer Center of Kansas   (United States)

^d Gabrail Cancer Center   (United States)

^e South Carolina Geodetic Survey   (United States)

^f Cancer Centers of America/Tulsa   (United States)

^g Cancer Care Centers of South Texas   (United States)

^h WEST CLINIC   (United States)

ⁱ TFS   (United States)

^j EMB Statistical Solutions   (United States)

^k Therapeutics Inc   (United States)

^l Drug Safety Navigator   (United States)

^m North Shore Hematology/Oncology Associates   (United States)

more..

Author keywords

chemotherapy induced nausea and vomiting (CINV); extended release granisetron; highly emetogenic chemotherapy (HEC)

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; DEXAMETHASONE; FOSAPREPITANT; GRANISETRON; MORPHOLINE DERIVATIVE; ONDANSETRON;

ADMINISTRATION AND DOSAGE; ADOLESCENT; ADULT; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VERY ELDERLY; VOMITING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; ONDANSETRON; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 84969961803     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2016-0070     Document Type: Article

References (38)

1. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J. Clin. Oncol. 24(27), 4472-4478 (2006).
2. Basch E, Prestrud AA, Hesketh PJ et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 29(31), 4189-4198 (2011).
3. Aapro M, Molassiotis A, Dicato M et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER). Ann. Oncol. 23(8), 1986-1992 (2012).
4. Hilarius DL, Kloeg PH, Van Der Wall E, Van Den Heuvel JJ, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: A community hospital-based study. Support. Care Cancer 20(1), 107-117 (2012).
5. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 h after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J. Clin. Oncol. 23(6), 1289-1294 (2005).
6. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapyinduced nausea and vomiting: results of the Perugia consensus conference. Ann. Oncol. 21(Suppl. 5), v232-v243 (2010).
7. NCCN Clinical Practice Guidelines in Oncology: Antiemesis-v2.2015. www.nccn.org
8. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A doubleblind, double-dummy, randomised, comparative Phase III trial. Lancet Oncol. 10(2), 115-124 (2009).
9. Aapro MS, Grunberg SM, Manikhas GM et al. A Phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapyinduced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol. 17(9), 1441-1449 (2006).
10. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a Phase III, single-dose trial versus dolasetron. Cancer 98(11), 2473-2482 (2003).
11. Gralla R, Lichinitser M, Van DV et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. 14(10), 1570-1577 (2003).
12. Matsumoto K, Takahashi M, Sato K et al. Palonosetron or granisetron for prevention of CINV in patients with breast cancer receiving dexamethasone and fosaprepitant following anthracycline plus cyclophosphamide (AC) regimen. J. Clin. Oncol. 33(Suppl.), Abstract 9598 (2015).
13. Hashimoto H, Yamanaka T, Shimada Y et al. Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, Phase III trial. J. Clin. Oncol. 31(Suppl.), Abstract 9621 (2013).
14. Ottoboni T, Gelder M, O'Boyle E. Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron. J. Exp. Pharmacol. 6, 15-21 (2014).
15. Heller J, Barr J. Biochronomer technology. Expert Opin. Drug Deliv. 2(1), 169-183 (2005).
16. Morrison D, Anderson A, Slama M et al. Phase 1 bioavailability study comparing 2 different subcutaneous routes of administration for APF530. Support. Care Cancer 23(Suppl.), Abstract 11-16-P (2015).
17. Gabrail N, Yanagihara R, Spaczynski M et al. Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase 2 trials. Cancer Manag. Res. 7, 83-92 (2015).
18. Raftopoulos H, Boccia R, Cooper B, O'Boyle E, Gralla R. Slow-release granisetron (APF530) vs palonosetron for chemotherapyinduced nausea/vomiting: analysis by ASCO emetogenicity criteria. Future Oncol. 11(18), 2541-2551 (2015).
19. Raftopoulos H, Cooper W, O'Boyle E, Gabrail N, Boccia R, Gralla RJ. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority Phase 3 trial. Support. Care Cancer 23, 723-732 (2015).
20. Boccia RV, Cooper W, O'Boyle E. Sustained antiemetic responses with APF530 (sustainedrelease granisetron) during multiple cycles of emetogenic chemotherapy. J. Commun. Support. Oncol. 13, 38-46 (2015).
21. Varubi (rolapitant) tablets, for oral use, package insert. Tesaro, Inc., Waltham, MA, USA. www.accessdata.fda.gov
22. Akynzeo (netupitant and palonosetron) capsules, for oral use, prescribing information. Eisai, Inc., Woodcliff Lake, NJ, USA. www.akynzeo.com
23. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12), 3090-3098 (2003).
24. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75(4), 800-802 (1988).
25. Aapro M, Rugo H, Rossi G et al. A randomized Phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann. Oncol. 25(7), 1328-1333 (2014).
26. Rapoport BL. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region. Curr. Med. Res. Opin. 30(9), 1875-1881 (2014).
27. Hesketh PJ, Rossi G, Rizzi G et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: A randomized dose-ranging pivotal study. Ann. Oncol. 25(7), 1340-1346 (2014).
28. Rapoport BL, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support. Care Cancer 18(4), 423-431 (2010).
29. Rapoport BL, Chasen MR, Gridelli C et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, Phase 3 trials. Lancet Oncol. 16(9), 1079-1089 (2015).
30. Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 69(5), 515-533 (2009).
31. Aloxi (palonosetron HCl) injection for intravenous use, prescribing information. Eisai, Inc., Woodcliff Lake, NJ, USA (2014). www.aloxi.com/docs/pdf/pi.pdf
32. Schnadig I, Modiano MR, Poma A, Hedley ML, Martell RE, Schwartzberg LS. Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC). J. Clin. Oncol. 32(Suppl.), Abstract 9633 (2014).
33. Platinol (cisplatin for injection, USP), prescribing information. Bristol-Myers Squibb Company, Princeton, NJ, USA. www.accessdata.fda.gov
34. Depo-Provera CI (medroxyprogesterone acetate) injectable suspension, for intramuscular use, prescribing information. Pfizer, Inc., New York, NY, USA. http://labeling.pfizer.com
35. Lupron Depot (leprolide acetate for depot suspension), package insert. AbbVie, Inc., North Chicago, IL, USA. www.rxabbvie.com
36. Aoki S, Iihara H, Nishigaki M et al. Difference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitant. Mol. Clin. Oncol. 1(1), 41-46 (2013).
37. Longo F, Mansueto G, Lapadula V et al. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support. Care Cancer 19(8), 1159-1164 (2011).
38. Abe M, Hirashima Y, Kasamatsu Y et al. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 Phase II trial. Support. Care Cancer 24(2), 675-682 (2015).